Expert Video - What are the latest advances in treatment failure and relapse in AML?

Acute myeloid leukemia (AML) expert Dr. Jamile Shammo discusses recent advances in the understanding of AML disease biology, which is changing the outcomes for patients. The importance of improved outcomes with combination-agent, and triple-agent therapy is becoming a new therapeutic area of importance in treating AML patients. Personalized patient care is becoming increasingly important in the future management of AML patients. The classical approach to AML treatment is induction, consolidation, and maintenance therapy. The relapsed patient is an area of focus in the future. Mutations are drivers of AML disease. Experts provide their own updates, based on their own clinical experience.

Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about AML which will help other patients, caregivers and families.

Other Modules:

Understanding AML

Understanding AML-MRC and tAML

Understanding Erythropoiesis

Diagnosing AML, AML-MRC, and tAML

Treating AML

Treatment Failure and Relapse in AML

Animation - Maintenance and Continuous Treatment

Slide Show - Maintenance and Continuous Treatment

Expert Videos

1. What is personalized AML maintenance treatment?

2. What are the phases of AML treatment?

3. What treatment challenges do elderly patients face in AML?

4. What are the special considerations in treating frail elderly AML patients?

5. What are some of the approaches used in AML maintenance therapy?

$What are some of the FDA approved treatments for relapsed or refractory AML?$

6. What are some of the FDA approved treatments for relapsed or refractory AML?

7. What are the leading clinical trials in older patients with AML?

8. What are the latest advances in treatment failure and relapse in AML?

Patient Videos

9. Ed's story: What transfusions do you receive for your AML?

10. Paul's story: What has your experience been with AML maintenance treatment?

11. Paul's story: How have you managed side-effects from your AML maintenance treatment?

12. Paul's story: How has your AML treatment impacted your quality of life?

13. Paul's story: How is your AML being monitored and followed over time?

14. Paul's story: How long will you be on AML maintenance therapy?

15. Peggy's story: How is your AML being monitored while you receive maintenance therapy?

16. Peggy's story: How has your AML treatment impacted your quality of life?

This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.

This activity is supported by educational grants from AbbVie, Acceleron, Bristol-Myers Squibb, Celgene Corporation, Daiichi Sankyo, Jazz Pharmaceuticals and Takeda Oncology.

This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.